Opioid receptors in endothelium

Endothelial Biomedicine

Volumn , Issue , 2007, Pages 451-460

  Gupta, Kalpna ^a   Stephenson, Elliot J ^a  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 36448983433     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1017/CBO9780511546198.051     Document Type: Chapter

References (63)

1. Waldhoer M, Bartlett SE, Whistler JL. Opioid receptors. Annu Rev Biochem. 2004; 73:953–990.
2. Gupta K, Kshirsagar S, Chang L, et al.Morphine stimulates angiogenesis by activating proangiogenic and survival-promoting signaling and promotes breast tumor growth. Cancer Res. 2002; 62:4491–4498.
3. Granata F, Potenza RL, Fiori A, et al. Expression of OP4 (ORL1, NOP1) receptors in vascular endothelium. Eur J Pharmacol. 2003; 482:17–23.
4. Polte T, Schroder H.CyclicAMPmediates endothelial protection by nitric oxide. Biochem Biophys Res Commun. 1998; 251:460– 465.
5. Arai M, Thurman RG, Lemasters JJ. Contribution of adenosine A(2) receptors and cyclic adenosine monophosphate to protective ischemic preconditioning of sinusoidal ECs against storage/reperfusion injury in rat livers. Hepatology. 2000; 32:297–302.
6. Law PY, Loh HH. Regulation of opioid receptor activities. J Pharmacol Exp Ther. 1999; 289:607–624.
7. Stiene-Martin A, Zhou R, Hauser KF. Regional, developmental, and cell cycle-dependent differences in mu, delta, and kappaopioid receptor expression among cultured mouse astrocytes. Glia. 1998; 22:249–259.
8. Hellewell SB, Bowen WD. A sigma-like binding site in rat pheochromocytoma (PC12) cells: decreased affinity for (+)-benzomorphans and lower molecular weight suggest a different sigma receptor form from that of guinea pig brain. Brain Res. 1990; 527:244–253.
9. Tryoen-Toth P, Gaveriaux-Ruff C, Maderspach K, et al. Regulation of kappa-opioid receptor mRNA level by cyclic & and growth factors in cultured rat glial cells. Brain ResMol Brain Res. 1998; 55:141–150.
10. Chang SL, Moldow RL, Wu G-d, et al. The association between opiates and cytokines. Adv Exp Med Biol. 1998; 437:4–6.
11. Jenab S, Inturrisi CE. Ethanol and naloxone differentially upregulate delta opioid receptor gene expression in neuroblastoma hybrid(NG108–15) cells. Brain ResMol Brain Res. 1994; 27:95–102.
12. Chen C, Farooqui M, Gupta K. Morphine stimulates VEGF-like signaling in mouse retinal ECs. Curr Neurovas Res. 2006; 3:171– 180.
13. Brown LF, Yeo KT, Berse B, et al. Expression of vascular permeability factor (vascular endothelial growth factor) by epidermal keratinocytes during wound healing. J ExpMed. 1992; 176:1375– 1379.
14. Finn AK, Whistler JL. Endocytosis of the mu opioid receptor reduces tolerance and a cellular hallmark of opiate withdrawal. Neuron. 2001; 32:829–839.
15. Whistler JL, Enquist J, Marley A, et al.Modulation of postendocytic sorting of G protein-coupled receptors. Science. 2002; 297: 615–620.
16. Whistler JL, Chuang HH, Chu P, et al. Functional dissociation of mu opioid receptor signaling and endocytosis: implications for the biology of opiate tolerance and addiction. Neuron. 1999; 23:737–746.
17. Stefano GB, Hartman A, Bilfinger TV, et al. Presence of themu3 opiate receptor in ECs. Coupling to nitric oxide production and vasodilation. J Biol Chem. 1995; 270:30290–30293.
18. Cadet M, Mantione KJ, Stefano GB. Molecular identification and functional expression of mu3, a novel alternatively spliced variant of the humanmu opiate receptor gene. J Immunol. 2003; 170:5118–5123.
19. Stefano GB, Salzet M, Hughes TK, et al. Delta-2 opioid receptor subtype on human vascular endothelium uncouples morphine stimulated nitric oxide release. Int J Cardiol. 1998; 64(Suppl 1): S43–S51.
20. Arendt RM, Schmoeckel M, Wilbert-Lampen U, et al. Bidirectional effects of endogenous opioid peptides on endothelin release rates in porcine aortic EC culture: mediation by delta opioid receptor and opioid receptor antagonist-insensitive mechanisms. J Pharmacol Exp Ther. 1995; 272:1–7.
21. Melzig MF, Heder G, Siems WE, et al. Stimulation of endothelial angiotensin-converting enzyme by morphine via non-opioid receptor mediated processes. Pharmazie. 1998; 53:634–637.
22. Pasi A, Qu BX, Steiner R, et al. Angiogenesis: modulation with opioids. Gen Pharmacol. 1991; 22:1077–1079.
23. Tegeder I, Geisslinger G. Opioids as modulators of cell death and survival – unraveling mechanisms and revealing new indications. Pharmacol Rev. 2004; 56:351–369.
24. Suzuki S, Chuang LF, Doi RH, et al. Morphine suppresses lymphocyte apoptosis by blocking p53-mediated death signaling. Biochem Biophys Res Commun. 2003; 308:802–808.
25. Polakiewicz RD, Schieferl SM, Gingras AC, et al. Muopioid receptor activates signaling pathways implicated in cell survival and translational control. J Biol Chem. 1998; 273:23534–23541.
26. Hou YN, Vlaskovska M, Cebers G, et al. A mu-receptor opioid agonist induces AP-1 and NF-kappa B transcription factor activity in primary cultures of rat cortical neurons.Neurosci Lett. 1996; 212:159–162.
27. Xie P, Browning DD, Hay N, et al. Activation of NF-kappa B by bradykinin through a Galpha(q)-and Gbeta gamma-dependent pathway that involves phosphoinositide 3-kinase and Akt. J Biol Chem. 2000; 275:24907–24914.
28. Law PY, Bergsbaken C. Properties of delta opioid receptor in neuroblastoma NS20Y: receptor activation and neuroblastoma proliferation. J Pharmacol Exp Ther. 1995; 272:322–332.
29. Law PY, McGinn TM, Campbell KM, et al. Agonist activation of delta-opioid receptor but not mu-opioid receptor potentiates fetal calf serumor tyrosine kinase receptor-mediated cell proliferation in a cell-line-specificmanner.MolPharmacol. 1997; 51:152– 160.
30. Murohara T, Asahara T, Silver M, et al. Nitric oxide synthase modulates angiogenesis in response to tissue ischemia. J Clin Invest. 1998; 101:2567–2578.
31. Wetzker R, Bohmer F-D. Transactivation joinsmultiple tracks to the ERK/MAPK cascade. Nat Rev. 2003; 4:651–657.
32. Belcheva MM, Szucs M, Wang D, et al. Mu-opioid receptormediated ERK activation involves calmodulin-dependent epidermal growth factor receptor transactivation. J Biol Chem. 2001; 276:33847–33853.
33. Belcheva MM, Tan Y, Heaton VM, et al. Mu opioid transactivation and down-regulation of the epidermal growth factor receptor in astrocytes: Implications for mitogen-activated protein kinase signaling. Mol Pharmacol. 2003; 64:1391–1401.
34. Machelska H, Brack A, Mousa SA, et al. Selectins and integrins but not platelet-EC adhesion molecule-1 regulate opioid inhibition of inflammatory pain. Br J Pharmacol. 2004; 142:772–780.
35. Stefano GB, Salzet M, Bilfinger TV. Long-term exposure of human blood vessels to HIV gp120, morphine, and anandamide increases endothelial adhesion of monocytes: uncoupling of nitric oxide release. J Cardiovasc Pharmacol. 1998; 31:862–868.
36. Chang SL, Moldow RL, House SD, et al. Morphine affects the brain-immune axis by modulating an interleukin-1 dependent pathway. In: Friedman H, Eisenstein T, Madden J, Sharp B, eds. AIDS, Drugs of Abuse and the Neuroimmune Axis. New York: Plenum Publishing Corp., 1996:35–42.
37. Magazine HI, Liu Y, Bilfinger TV, et al.Morphine-induced conformational changes in human monocytes, granulocytes, and ECs and in invertebrate immunocytes and microglia are mediated by nitric oxide. J Immunol. 1996; 156:4845–4850.
38. Wang X, Douglas SD, Commons KG, et al. A non-peptide substance P antagonist (CP-96, 345) inhibits morphine induced NFkappa B promoter activation in human NT2-N neurons. J Neurosci Res. 2004; 75:544–553.
39. Frassdorf J, Weber NC, Obal D, et al. Morphine induces late cardioprotection in rat hearts in vivo: the involvement of opioid receptors and NF-kappa B. Anesth Analg. 2005; 101:934–941.
40. Roy S, Cain KJ, Chapin RB, et al.Morphine modulates NF kappa B activation in macrophages. Biochem Biophys Res Commun. 1998; 245:392–396.
41. Vallejo R, de Leon-Casasola O, Benyamin R. Opioid therapy and immunosuppression: a review. Am J Ther. 2004; 11:354–365.
42. Arerangaiah R, Chalasani N, Udager AM, et al. Opioids induce renal abnormalities in tumor bearing mice.Nephron ExpNephrol. 2007:In press.
43. Kodani E, Xuan YT, Shinmura K, et al. Delta opioid receptor induced lat preconditioning is mediated by cyclo-oxygense-2 in conscious rabbits. Am J Physiol Heart Circ Physiol. 2002; 283: H1943–H1957.
44. Patel HH, Hsu AK, Gross GJ.COX-2 and iNOS in opioid induced delayed cardioprotection in the intact rat. Life Sci. 2004; 75:129– 140.
45. Peart JN, Gross ER, Gross GJ. Opioid induced preconditioning: recent advances and future perspectives. Vasc Pharmacol. 2005; 42:211–218.
46. Poonawala T, Levay-Young BK, Hebbel RP, et al. Opioids heal ischemic wounds in the rat. Wound Repair and Regen. 2005; 13: 165–174.
47. Mitchell RN, Lichtman AH. The link between IFN-gamma and allograft arteriopathy: is the answer NO? J Clin Invest. 2004; 114: 762–764.
48. McBride SM, Smith-Sonneborn J, Oeltgen P, et al. Delta2 opioid receptor agonist facilitates mean arterial pressure recovery after hemorrhage in conscious rats. Shock. 2005; 23:264–268.
49. Zaugg M, Lucchinetti E, Uecker M, et al. Anaesthetics and cardiac preconditioning. Part I. Signalling and cytoprotective mechanisms. Br J Anaesth. 2003; 91:551–565.
50. Cao CM, Xia Q, Tu J, et al. Cardioprotection of interleukin-2 is mediated via kappa-opioid receptors. J Pharmacol Exp Ther. 2004; 309:560–567.
51. Shi E, Jiang X, Bai H, et al. Cardioprotective effects of morphine on rat heart suffering from ischemia and reperfusion. Chin Med J (Engl). 2003; 116:1059–1062.
52. Wang J, Barke RA, Charboneau R, et al. Morphine negatively regulates interferon-gamma promoter activity in activated murine T cells through two distinct cyclic AMP-dependent pathways. J Biol Chem. 2003; 278:37622–37631.
53. Pugsley MK, Walker MJ, Wong TM. Cardiovascular actions of the kappa-agonist U-50, 488H in the absence and presence of opioid receptor blockade. Br J Pharmacol. 1992; 105:521–526.
54. Kasamatsu K, Sapru HN. Attenuation of aortic baroreflex responses by microinjections of endomorphin-2 into the rostral ventrolateral medullary pressor area of the rat. Am J Physiol Regul Integr Comp Physiol. 2005; [Epub ahead of print].
55. Hanif K, Fahim M, Pavar MC, et al. Hypotensive effect of novel chimeric peptides of met-enkephalin and FMRFa. Regul Pept. 2005; 125:155–161.
56. Cozzolino D, Sasso FC, Salvatore T, et al. Acute effects of betaendorphin on cardiovascular function in patients with mild to moderate chronic heart failure. Am Heart J. 2004; 148:E13.
57. Marmor M, Penn A, Widmer K, et al. Coronary artery disease and opioid use. Am J Cardiol. 2004; 15:1295–1297.
58. Armstead WM. Relationship among NO, the KATP channel, and opioids in hypoxic pial artery dilation. Am J Physiol. 1998; 275: H988–H994.
59. Lim YJ, Zheng S, Zuo Z. Morphine preconditions Purkinje cells against cell death under in vitro simulated ischemia-reperfusion conditions. Anesthesiol. 2004; 100:562–568.
60. Sachs D, Cunha FQ, Ferreira SH. Peripheral analgesic blockade of hypernociception: activation of arginine/NO/cGMP/protein kinase G/ATP-sensitive K+ channel pathway. Proc Natl Acad Sci USA. 2004; 101:3680–3685.
61. Bigliardi PL, Sumanovski LT, Buchner S, et al. Different expression of mu-opiate receptor in chronic and acute wounds and the effect of beta-endorphin on transforming growth factor beta type II receptor and cytokeratin 16 expression. J InvestDermatol. 2003; 120:145–152.
62. Gupta K, Zhang J. Angiogenesis: a curse or cure? PostgradMed J. 2005; 81:236–42.
63. Farooqui M, Geng ZH, Stephenson EJ, et al. Naloxone acts as an antagonist of estrogen receptor in MCF7 cancer cells.Mol Cancer Ther. 2006; 5:611–620.